Condition
Exanthema
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Not Yet Recruiting1
Unknown1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06399029Phase 2Active Not RecruitingPrimary
Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities
NCT07112846Not Yet RecruitingPrimary
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
NCT03102905Unknown
Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?
Showing all 3 trials